Dr. Leah M. Mccrary, MD
Infectious Disease (Infectious Disease Physician)
620 S Taylor Ave, Div Im Infectious Disease, Ste 100
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 37
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
MO license 2023013765 -
Internal Medicine Physician
MO license 2023013765
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 37
- Services billed
- 74
- Patients’ average age
- 70
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ceftriaxone (ceftriaxone sodium) Other prescribers in Saint Louis, MO | 19 |
| Doxycycline Hyclate Other prescribers in Saint Louis, MO | 13 |
| Mavyret (glecaprevir/pibrentasvir) | 13 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Saint Louis, MO | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 25 payments worth $4,670 in total to this clinician.
| Gilead Sciences, Inc. | $4,670 |
|---|
| Consulting Fee | $2,090 |
|---|---|
| Travel and Lodging | $1,489 |
| Education | $825 |
| Food and Beverage | $265 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Jul 27, 2025 | Travel and Lodging travel to Atlanta, GA Company’s description;4298105;GTF;12972335 | $1,341 |
| Gilead Sciences, Inc. Jul 27, 2025 | EducationCompany’s description;4298011;GTF;12972335 | $825 |
| Gilead Sciences, Inc. Aug 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Sep 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Oct 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Nov 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Dec 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Jan 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Feb 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Mar 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Dec 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Nov 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Oct 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Sep 9, 2025 | Travel and Lodging travel to St. Louis, MO Company’s description;4298039;GTF;12972335 | $148 |
| Gilead Sciences, Inc. Sep 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Aug 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $175 |
| Gilead Sciences, Inc. Jul 27, 2025 | Travel and Lodging travel to Atlanta, GA Company’s description;4298105;GTF;12972335 | $1,341 |
| Gilead Sciences, Inc. Jul 27, 2025 | EducationCompany’s description;4298011;GTF;12972335 | $825 |
| Gilead Sciences, Inc. Jul 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Jun 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. May 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Apr 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Mar 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Feb 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
| Gilead Sciences, Inc. Jan 1, 2025 | Consulting FeeCompany’s descriptionFunding to support the implementation of innovative public health screening programs for infectious diseases and development of best practices in such programs. Reportable recipients do not provide medical services to patients as a part of their role with the FOCUS Program or in the Organization's F | $174 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.